Compared with non-LN SLE, LN patients had higher serum level of anti-double-stranded (ds) DNA antibodies (P = 0.015) and lower serum level of complement C3 (P < 0.001), reflecting higher disease activity (SLEDAI, P < 0.001). The gene discussed is C3; the disease is systemic lupus erythematosus.